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Abstract
Objectives. Assess the effectiveness and safety of biologic therapy as well as predictors of response at 1
year of therapy, retention rate in biologic treatment and predictors of drug discontinuation in JIA patients
in the Portuguese register of rheumatic diseases.
Methods. We prospectively collected patient and disease characteristics from patients with JIA who
started biological therapy. Adverse events were collected during the follow-up period. Predictors of re-
sponse at 1 year and drug retention rates were assessed at 4 years of treatment for the first biologic
agent.
Results. A total of 812 JIA patients [65% females, mean age at JIA onset 6.9 years (S.D. 4.7)], 227 received
biologic therapy; 205 patients (90.3%) were treated with an anti-TNF as the first biologic. All the param-
eters used to evaluate disease activity, namely number of active joints, ESR and Childhood HAQ/HAQ,
decreased significantly at 6 months and 1 year of treatment. The mean reduction in Juvenile Disease
Activity Score 10 (JADAS10) after 1 year of treatment was 10.4 (S.D. 7.4). According to the definition of
improvement using the JADAS10 score, 83.3% respond to biologic therapy after 1 year. Fourteen patients
discontinued biologic therapies due to adverse events. Retention rates were 92.9% at 1 year, 85.5% at 2
years, 78.4% at 3 years and 68.1% at 4 years of treatment. Among all JIA subtypes, only concomitant
therapy with corticosteroids was found to be univariately associated with withdrawal of biologic treatment
(P = 0.016).
Conclusion. Biologic therapies seem effective and safe in patients with JIA. In addition, the retention rates
for the first biologic agent are high throughout 4 years.
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. Our data from Reuma.pt suggest that biologic therapies seem effective and safe in patients with JIA.
. The majority of patients with JIA respond to therapy after 1 year of biologic treatment.
. Long-term retention in biologic treatment is high in JIA patients.
Introduction
JIA is the most common rheumatic disease of childhood,
affecting 1/1000 children, and includes a heterogeneous
group of chronic arthritis of unknown aetiology that begins
before 16 years of age. According to disease onset, seven
categories can be identified [1].
The management of JIA has traditionally been modelled
on the RA treatment strategy, with MTX and, more re-
cently, biologic medications forming the mainstay of ther-
apy [26]. When inflammatory activity is not controlled
with MTX or if MTX is not tolerated, the next therapeutic
step is usually the addition of a TNF inhibitor (with the
exception of systemic JIA), either alone or in combination
with MTX [7]. However, JIA is an umbrella term for a group
of childhood-onset arthritides, many of which are quite
different from RA. Knowing that the JIA ILAR categories
represent, in fact, different diseases, the response to anti-
TNF therapies may also differ according to the subtype of
the disease. To date, there are currently five biologics
licensed for the treatment of JIA: etanercept, abatacept,
adalimumab, tocilizumab and canakinumab. Other bio-
logic options are under evaluation and some are often
prescribed off-label.
Large registries played a crucial role in analysing the
effectiveness and long-term safety of biologic treatments
in JIA [811]. However, little information is available from
registries that include JIA patients starting biologics at any
age, including adulthood. Moreover, data on predictors of
response to biologic therapy and long-term retention rates
are scarce.
In 2008, the Portuguese Society of Rheumatology de-
veloped an observational registry of patients with rheum-
atic diseases, including JIA, the Portuguese Register of
Rheumatic Diseases (Reuma.pt) [12]. In 2012, national
recommendations for the use of biologic therapies in chil-
dren and adolescents with JIA were updated, supporting
physicians in their therapeutic decisions [13]. The use of
biologic therapy in Portugal is limited to those patients
who are either intolerant to MTX and/or have arthritis ac-
tivity that is not controlled by MTX [13].
This study aims to assess the effectiveness of the first
biologic therapy at 6 months and 1 year of treatment as
well as safety during the overall follow-up period in JIA
patients registered in Reuma.pt. Our secondary objectives
were to study the predictive factors of response to treat-
ment at 1 year, the retention rate at 4 years of biologic
treatment and the factors associated with biologic drug
withdrawal in the treatment of JIA.
Methods
Our study was based on Reuma.pt, which includes JIA
patients receiving biologic therapies and synthetic
DMARDs. Our study was approved by the scientific com-
mittee of Reuma.pt. Reuma.pt is approved by the National
Commission for Data Protection. All patients fulfilled the
ILAR criteria for the classification of JIA [1].
We analysed all patients with a diagnosis of JIA regis-
tered in Reuma.pt until September 2013, irrespective of
age at entry into the cohort (patients who started biologic
therapy in adulthood were also included). At the start of
biologic treatment (baseline), we collected the following
data: age, gender, JIA category, age at JIA onset, disease
duration, number of active joints, patient’s pain visual ana-
logue scale (VAS), patient’s disease global activity VAS,
physician’s global disease activity VAS, extra-articular
manifestations, Childhood HAQ (CHAQ) or HAQ (as ap-
propriate) [14], ESR, CRP and concomitant therapy with
DMARDs and/or corticosteroids. Follow-up data were
considered during the first biologic therapy.
Follow-up data for effectiveness (disease activity) were
obtained at 6 months and 1 year after starting the first
biologic and included the number of active joints, ESR
and CHAQ/HAQ. To calculate response to treatment we
used the delta Juvenile Disease Activity Score (JADAS), a
recent composite score found to be a valid instrument for
assessment of disease activity in JIA [15] and, in addition,
the definition of improvement using the JADAS10 [16].
According to this new definition of improvement using
the JADAS [16], if the JADAS10 baseline was between
5 and 15 (low disease activity), there is a response to
therapy if delta JADAS is >4; if the JADAS10 baseline is
between 15 and 25 (moderate disease activity), there is a
response to therapy if delta JADAS is >10; and if the
JADAS10 baseline is between 25 and 40 (high disease
activity), there is a response to therapy if delta JADAS is
>17. Safety analysis (severe adverse events) was per-
formed with the cumulative events at the end of the
follow-up. Retention rates for the first biologic were
calculated yearly in the first 4 years of treatment. The
reason for biologic withdrawal was also collected.
Statistical analysis
Each patient contributed data regarding the course of
their first biologic treatment only.
In order to study retention rates, we included only pa-
tients with follow-up periods of at least 1 year. Drug re-
tention rates were calculated using the KaplanMeier
method.
The Cox regression model was used to identify pre-
dictors of drug discontinuation until 4 years, so patients
were censored at the time of last consultation or at 4 years
of treatment, whichever came first. At first, crude hazard
ratios were obtained using all JIA categories combined.
Subsequently the analysis was repeated using only pa-
tients with polyarthritis (polyarticular RF positive, polyarti-
cular RF negative and extended oligoarticular JIA). The
698 www.rheumatology.oxfordjournals.org










 Portugal user on 16 D
ecem
ber 2020
proportional hazards assumption was verified. As a sec-
ondary analysis, we repeated all of the main analyses
using only the patients that started biologic treatment
before the age of 18 years. Statistical analysis was
made in R version 2.15.3 (R Project for Statistical
Computing, Vienna, Austria) [17].
Results
Twenty-one centres and 77 clinicians across the country
contributed data for this study. Of the 812 patients with
JIA registered in Reuma.pt [mean age 19.9 years (S.D.
11.3), 65% females, mean age at JIA onset 6.9 years
(S.D. 4.7)], 227 received biologic therapy and the median
duration of the first biologic agent treatment was 4.5 years
[interquartile range (IQR) 2.25.9] (the characteristics of
the patients treated with biologic agents are presented
in Table 1). The mean age at disease onset of JIA patients
ever treated with biologic DMARDs was 7.5 years (S.D. 4.9;
IQR 0.811.6) and the mean age for starting biologic ther-
apy was 16.2 years (S.D. 9.4; IQR 1.820.4). Sixty-nine
(30.4%) patients started biologic therapy in adulthood.
Most patients (90.3%) were treated with anti-TNF as a
first line treatment: etanercept 69.2% (157 patients), ada-
limumab 12.8% (29 patients) and infliximab 8.4% (19 pa-
tients). All patients taking anakinra (4.8%) had systemic
JIA (Table 2). During the follow-up, 32 (14.1%) patients
switched biologic treatment once, 13 (5.7%) patients
switched twice, 2 (0.9%) switched three times, 3 (1.3%)
patients switched four times and 1 (0.4%) patient
switched five times.
Twenty-eight patients had uveitis and 10 of them were
treated with infliximab.
In the subgroup of patients who started biologic therapy
as adults (30.4%), there was a greater proportion of
female patients (76.8% vs 59.5%, P = 0.02), older age at
JIA onset [9.5 years (S.D. 5.3) vs 6.6 (S.D. 4.5), P< 0.0001]
and longer overall disease duration [24.4 years (S.D. 11.3)
vs 9.5 (S.D. 5.3), P< 0.0001] compared with those who
started in childhood. The proportion of each category of
JIA in the two subgroups was similar, as well as the dis-
tribution of the first biologic agent used.
Effectiveness of biologic treatment
All the parameters used to evaluate disease activity,
namely the number of active joints, ESR and CHAQ/
HAQ, decreased significantly at 6 months and 1 year of
treatment with biologic agents. The mean active joint
count reported at the beginning of biologic
therapies was 5.1 (S.D. 5.8) and decreased to 1.2 (S.D. 2.4;
P < 0.0001) and 1.0 (S.D. 3.1; P < 0.0001) after 6 months
and 1 year of therapy, respectively (Fig. 1A). Mean ESR
was 33.9 mm/first hour (S.D. 25.3) at biologic treatment
start and was of 22.0 (S.D. 24.0; P< 0.001) and
19.1 (S.D. 18.0; P < 0.0001) after 6 months and 1 year of
treatment, respectively (Fig. 1B). The mean CHAQ/HAQ
decreased from 0.8 (S.D. 0.7) at baseline to 0.4 (S.D. 0.5;
P< 0.0001) at 6 months and 0.4 (S.D. 0.5; P < 0.0001) at
1 year (Fig. 1C). In accordance, the mean CRP was
2.4 mg/dl (S.D. 3.7) at biologic treatment start and of
1.2 (S.D. 3.3) at 6 months (P = 0.043) and 0.6 (S.D. 1.1) at 1
year (P < 0.0001). Patient global disease activity, evalu-
ated by VAS, was 43.5 mm (S.D. 26.5) at baseline,
18.2 (S.D. 19.6) at 6 months (P< 0.0001) and
16.3 (S.D. 17.7) at 1 year (P < 0.0001).
Safety analysis
The total length of exposure to the first biologic agent was
706.92 patient-years and, during the follow-up period,
there were 1.98 events/100 patient-years. A total of 14
clinically significant adverse events (defined by the need
for biologic treatment discontinuation) were reported,
including infusion reaction (one patient), respiratory and
urinary infections (six patients), inflammatory bowel dis-
ease (four patients), diarrhoea (one patient), tuberculin





Total number of patients 227
Gender, female/male, n (%)/n (%) 147 (64.8)/80(35.2)
Age at disease onset,
mean (S.D.), years
7.5 (4.9)
Disease duration, mean (S.D.), years 13.7 (10.1)
JIA categories fulfilled, n 206
JIA category not stated, n 21
Persistent oligoarticular, n (%) 20 (9.7)
Extended oligoarticular, n (%) 33 (16)
Polyarticular RF positive, n (%) 36 (17.5)
Polyarticular RF negative, n (%) 48 (23.3)
Systemic, n (%) 28 (13.6)
Enthesitis-related arthritis, n (%) 31 (15.1)
Psoriatic arthritis, n (%) 10 (4.8)
Unclassified, n 0
TABLE 2 Patient (N = 227) and disease characteristics
treated with biologic agents
Characteristic Value
Age, mean (S.D.), years 16.2 (9.4)
Total amount of biologic treatment
exposure, mean (S.D.), years
4.5 (3.1)
Concomitant DMARD therapy, n (%) 181 (79.7)
Methotrexate 170 (93.9)
Sulfasalazine 16 (8.8)
Other DMARDs 11 (6.1)
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skin test conversion (one patient) and active tuberculosis
(one patient).
There were no reported deaths or malignancies during
the overall follow-up period of biologic treatment, 134
treatments were stopped for the following reasons: 14
(10.5%) due to an adverse event, 60 (44.8%) due to a
lack/loss of efficacy (primary or secondary failure), 13
(9.7%) due to disease remission, 2 (1.49%) were lost to
follow-up, 4 (3%) refused to continue treatment and 40
(29.8%) for other reasons (not specified).
Predictors of treatment response at 1 year
The mean reduction in JADAS10 after 1 year of treatment
was 10.4 (S.D. 7.4) [median 9.9 (IQR 4.813.7)]. According
to the definition of improvement using the JADAS10 score
[16], 58 individuals had registered information of the vari-
ables that allowed determining JADAS10 response at 1
year of biologic therapy: 83.7% responded to therapy at
6 months of biologic treatment and 83.3% responded to
biologic therapy after 1 year. These 58 individuals were
comparable to the ones excluded regarding disease cat-
egory (P = 0.397), however, they were younger (mean age
13.5 vs 17.3 years, P = 0.013) and more likely to be male
(53% vs 30%, P = 0.002). Due to the small number of pa-
tients and high proportion of responders, there was no
possibility of calculating the predictors of response to bio-
logic therapy using a binary outcome.
Retention rate and predictors of drug discontinuation
A total of 179 patients were followed up for >1 year after
the beginning of the first biologic therapy, and the median
treatment duration was 5.8 years (IQR 4.88.3). The reten-
tion rates with the first biologic were 92.9% (CI 88.5, 97.5)
in the first year, 85.5% (CI 79.5, 91.9) in the second year,
78.4% (CI 71.4, 86.1) in the third year and 68.1% (CI 59.7,
77.7) in the fourth year of treatment (Fig. 2).
Taking all JIA categories into consideration, only con-
comitant therapy with systemic corticosteroids at baseline
was found to be crudely associated with withdrawal of
biologic treatment [hazard ratio (HR) 1.93 (95% CI 1.13,
3.29), P = 0.016]. However, this association showed low
statistical significance when adjusting for the other clinic-
ally relevant covariates [HR 1.47 (95% CI 0.64, 3.38),
P = 0.362]. We found a higher risk of biologic drug with-
drawal among systemic JIA patients [HR 2.32 (95% CI
1.19, 4.52), P = 0.014] compared with the polyarticular
categories of disease. In addition, we failed to identify
any predictors of drug discontinuation in the stratified
analysis using the polyarticular categories of disease.
We analysed separately the subgroup of patients that
started biologic therapies in childhood. In these patients,
the retention rates were similar to those of patients who
started biologic treatment in adulthood.
Discussion
This article presents the results from the Portuguese na-
tional register in which we consecutively included all
FIG. 1 Evolution of the disease parameters in the first year of biologic treatment
Evolution of the (A) active joint count, (B) ESR and (C) CHAQ/HAQ in the first year after the beginning of biologic
treatment. CHAQ: Childhood Health Assessment Questionnaire.
FIG. 2 Drug survival on the first biologic agent
(KaplanMeier plot)
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patients with JIA treated with biologic therapies. The dis-
tribution of JIA categories in our registry is similar to those
found in recently published inception cohorts [1820].
These data prove, in a real-life setting with an unselected
population, the sustained effectiveness and safety of bio-
logic treatments in all JIA categories as highlighted by a
high retention rate after 4 years of treatment. Etanercept
was the most frequently used TNF inhibitor, most likely
because it was the first biologic agent approved for JIA
treatment [2].
There were few cases (20 patients) of persistent oligoar-
ticular JIA treated with biologics, in agreement with the
Portuguese guidelines for prescribing biologic therapy in
JIA [13]. Paediatric rheumatologists often need to pre-
scribe TNF blocking agents in oligoarticular JIA due to
disabling active oligoarthritis or related to the higher
prevalence of uveitis in this category. In multivariable
models, uveitis was strongly and independently asso-
ciated with non-biologic and biologic DMARD use. This
implies that uveitis may frequently be the determining
factor in the systemic treatment of children with oligoarti-
cular JIA [1823]. Nevertheless, there are no published
sizable randomized studies of the systemic treatment of
uveitis in children [24]. More research in this area is
needed.
Biologic agents were safe during the overall follow-up
period of treatment. Infections, particularly tuberculosis,
are a concern for every physician prescribing biologic
agents. In our study, and despite previous screening,
there was one case of pulmonary tuberculosis associated
with the use of a monoclonal antibody (adalimumab), and
in one patient taking etanercept, we found a tuberculin
skin test conversion that led to discontinuation of biologic
therapy. Four patients were diagnosed with chronic in-
flammatory bowel disease (IBD) during biologic treatment,
all with etanercept. Several other cases of new-onset IBD
during etanercept use were reported [2530]. The mech-
anism behind this effect is still unknown and more re-
search is required in this field. We did not find any
discontinuations associated with the development of
psoriasis, lupus-like or other chronic inflammatory or
autoimmune diseases. No cases of malignancy were
observed.
We have observed a large gap between the mean age
at disease onset of JIA patients ever treated with biologic
agents [7.5 years (S.D. 4.9)] and the mean age for starting
biologic therapy [16.2 years (S.D. 9.4)]: almost 10 years be-
tween disease onset and the beginning of biologic treat-
ment. This could be related in part to the long disease
duration of the adults with JIA starting biologics in adult-
hood and also to the retrospective insertion of these data
in the registry, with a large proportion of patients being
diagnosed before the approval of biologic therapies in na-
tional policies. Almost one-third of the patients included in
this study started biologic treatment as an adult, a fact
that is unusual in other JIA registries. Although innovative,
we are aware that this could have introduced a bias in the
results, since in patients with prolonged disease duration,
the outcomes may be quite different from those of
children starting biologics far earlier in their disease evo-
lution. Although we believe that including adults with JIA
brings an added value to our registry and data, the instru-
ments to measure disease activity in JIA have never been
validated for adults, and this should be taken into account
when analysing the data. More studies including adults
with JIA are necessary to validate these instruments in
this population.
TNF inhibitors are not always effective or universally
tolerated, which may lead to switching among biologic
agents. In our study, 22.5% of the patients switched bio-
logic treatment during their disease course. This propor-
tion is higher than the 10% reported from biologics
registries in the UK [6] and the Netherlands [31], but is
lower than the 35% reported from Finland [32] and the
28% reported in the USA [18].
Patients with JIA had a high retention rate of biologic
treatment in the first 4 years of therapy: 93% remained
on treatment in the first year and 68% in the first 4 years of
treatment. The retention rates found in our study were
similar to the JIA British cohort [6]. The prolonged use of
biologic agents suggests that for the majority of patients
the drug was effective and well tolerated.
Although we found a crude association between treat-
ment withdrawal and corticosteroid use, we found this
association to be at least partly confounded by the
CHAQ/HAQ score at baseline. In addition, this finding
was not confirmed in the polyarticular category of JIA.
Thus we cannot associate with certainty concomitant
therapy with systemic corticosteroids and discontinuation
of biologic treatment. We also found a higher risk of drug
cessation among systemic arthritis patients, and this
group has been proposed previously to be associated
with a poorer response to etanercept [33, 34].
This study is purely observational and the sample might
not be completely representative of the JIA population
since most patients [526 (65%)] were from rheumatology
centres in Lisbon. We choose the JADAS10 score as our
outcome measure for treatment response, although this
instrument has limitations, as pointed out by its authors.
Due to the small number of patients and high proportion of
responders, there was no possibility of calculating the
predictors of response to biologic therapy.
The lack of follow-up information on limited joint count
precluded the use of the ACR Pediatric response criteria.
The JADAS calculation may have had some limitations in
our study population. As the authors of the JADAS point
out, although the score was designed to be robust enough
to cover all categories of JIA, a thorough assessment of
disease activity in children with systemic JIA requires
quantification of extra-articular manifestations, particularly
fever and rash. Missing data and the small number of pa-
tients with available information for calculating response
to treatment limited the use of multivariate models and
stratified analyses by disease category. Because labora-
tory tests are frequently missing, in accordance with
McErlane et al. [35], our group also tested the JADAS
with and without ESR [36]. The correlation between the
JADAS with ESR and JADAS without ESR (clinical JADAS
www.rheumatology.oxfordjournals.org 701
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or three-variable JADAS) was high (r = 0.97, P = 0.0001),
indicating that when ESR is not available, the JADAS
can be calculated without this variable, allowing the meas-
urement of disease activity anytime and anywhere.
Another limitation concerns the decision to report an ad-
verse event, which is up to the treating physician, and
physicians probably reported only the clinically relevant
ones, which might have led to underreporting compared
with controlled clinical trials.
Conclusion
Our data from Reuma.pt reinforce that biologic therapies
seem effective and safe in all JIA categories. In addition,
retention rates with the first biologic agent were high
during the first 4 years of treatment.
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